
Three of the researchers behind the study, Kanchan Kumari Francesca Aguilo Margalida Esteva, Department of Molecular Biology.
Photo Credit: Mattias Pettersson
Scientific Frontline: "At a Glance" Summary
- Discovery: Researchers at Umeå University identified a novel mechanism in triple-negative breast cancer wherein the enzyme fibrillarin fine-tunes protein production to facilitate tumor growth and adaptation.
- Mechanism: Fibrillarin regulates the 2′-O-methylation (Nm) of ribosomal RNA and collaborates with the ribosomal protein RPS28 to construct specialized ribosomes with distinct translational capabilities.
- Specific Consequence: The depletion of fibrillarin causes a concurrent loss of RPS28, resulting in ribosomal heterogeneity—an imbalance of ribosome types that alters the proteome and drives oncogenic development.
- Context: This research shifts the understanding of cancer etiology beyond solely genetic mutations to include translational control, demonstrating how aggressive cells manipulate protein synthesis machinery.
- Implication: The findings suggest that targeting the ribosome assembly and modification machinery could serve as a new therapeutic strategy for treating aggressive cancers defined by misregulated protein production.
.jpg)
.jpg)

.jpg)




